Introduction
Previous studies showed that intensive glucose control (IGC), in which the target blood glucose level was set within 80-110 mg per 100 ml, reduced infections, dysfunction of organs including the liver and kidney and mortality compared to patients who received standard glucose control. [1] [2] [3] Although these results have been confirmed in several subsequent studies, 4 -7 the precise mechanism that underlies this association is unclear. In animal models, it has been shown that insulin itself has a direct inhibitory effect on the inflammation process. 8, 9 However in human studies, it has been suggested that these benefits could be directly attributed to IGC rather than to any pharmacological activity of administered insulin per se. 3, 4 Recipients of allogeneic hematopoietic SCT (HSCT), which is the most drastic therapeutic modality in patients with hematological malignancies, often suffer from serious complications including infectious diseases, GVHD and multiple organ failure. They are also at higher risk of hyperglycemia because of the use of steroids for the treatment of GVHD, the use of total parenteral nutrition (TPN), immunosuppressive drugs and infectious complications, 10, 11 which makes them further susceptible to numerous serious complications including infectious diseases and multiple organ failure. [12] [13] [14] Our group previously reported that hyperglycemia during neutropenia was associated with an increased risk of acute GVHD and nonrelapse mortality (NRM) after myeloablative allogeneic HSCT, 15 and that hyperglycemia during neutropenia was associated with a higher incidence of subsequent acute GVHD. It is well known that an increase in the levels of circulating cytokines may aggravate hyperglycemia, and hyperglycemia itself could increase the levels of cytokines. This vicious cycle could lead to elevated cytokine levels, which could lead to subsequent acute GVHD. With this background, it can be hypothesized that IGC would reduce the incidence of infectious diseases, acute GVHD and organ dysfunctions after allogeneic HSCT. Therefore, we prospectively investigated the effect of IGC after allogeneic HSCT, and compared the clinical outcomes to those in a matched cohort to address whether IGC following allogeneic HSCT could improve the clinical course of patients, that is, reduction of infectious diseases and organ dysfunction, as has been shown in the intensive care unit (ICU) setting.
Patients and methods

Patients
From June 2006 to May 2007, a total of 73 patients received allogeneic HSCT at the National Cancer Center Hospital (Tokyo, Japan); 60 patients were eligible for participation in this trial. Finally, 22 patients (36.7%) were enrolled in this IGC study to keep the blood glucose level at 80-110 mg per 100 ml, as shown in Figure 1 .
Study center and organization
The National Cancer Center Hospital in Tokyo holds 600 beds. The transplant team consists of 4 full-time physicians and 26 nursing staff who oversee 26 beds in the HSCT, and the entire ward is covered by high-efficiency particulate airfilters. We regularly perform 90-120 transplants per year: 80% allogeneic and 20% autologous.
Study design
This was a case-control study to investigate the clinical benefits of comprehensive nutritional support including IGC and parenteral nutrition (PN) management, which was approved by the Institutional Review Board. A matching control group was selected among patients who received HSCT from January 2002 to March 2007 (ratio of 1:2 compared to the study group) according to the following criteria: (1) conditioning regimen (conventional myeloablative or reduced intensity), (2) source of stem cells (BM, peripheral blood or cord blood), (3) age and (4) source of donor (related or unrelated). Criteria (1-4) were essential for inclusion. As a result, 42 matched controls were selected, and a total of 64 patients were subjected to further analysis (Table 1) .
Exclusion criteria
Exclusion criteria were as follows: (1) patients who received a reduced-intensity conditioning regimen for an HLAmatched related donor, as we applied GVHD prophylaxis without short-term MTX in this setting, and they had much less need for TPN and less need for intense glucose control, 16 (2) those with a poor performance status (Eastern Cooperative Oncology Group) X2, (3) those with uncontrolled infectious diseases at the beginning of the conditioning regimen and (4) those with preexisting neutropenia. We previously reported that the incidence of severe stomatitis (Common Terminology Criteria for Adverse Events (CTCAE) grade (3) was 0% after reduced-intensity SCT (RIST) from a related HLAmatched donor. 16 In this situation, the need for TPN and the incidence of hyperglycemia were quite low, compared to RIST from an unrelated donor, which included additional low-dose TBI or antithymocyte globulin (ATG) and shortterm MTX or conventional SCT with a myeloablative regimen. Hence, we only included patients who received a RIST regimen from an unrelated donor, who had a higher probability of glucose-control intervention, to evaluate the beneficial effects of IGC. per day Â 6 days) or cladribine (0.11 mg/kg per day Â 6 days) plus BU (oral 4 mg/kg per day Â 2 days or i.v. 3.2 mg/ kg per day Â 2 days). Low-dose TBI (2 or 4 Gy, n ¼ 10) and/or low-dose ATG (total dose 5-10 mg/kg ATG-F or 5 mg/kg thymoglobulin, n ¼ 15) were added. GVHD prophylaxis included CYA-(n ¼ 13) and tacrolimus-based regimens (n ¼ 51), with an additional short course of MTX. G-CSF was administered in all patients from day þ 6 after transplantation until engraftment. Most patients received ciprofloxacin (200 mg orally three times daily) for bacterial prophylaxis after the beginning of the conditioning regimen until neutrophil engraftment. Fluconazole (100 mg once daily) was administered for fungal prophylaxis after the beginning of the conditioning regimen. Low-dose acyclovir was given for prophylaxis against herpes simplex virus and VZV after the beginning of the conditioning regimen until immunosuppressive agents were discontinued. Prophylaxis against Pneumocystis jiroveci infection consisted of trimethoprim-sulfamethoxazole (400 mg of sulfamethoxazole once daily) from the first day of conditioning to day À3 of transplantation, and from day þ 28 until day þ 180 or the cessation of immunosuppressive agents. Patients who developed fever during the neutropenic period were treated with cefepime or other cephalosporin, and additional agents including vancomycin, aminoglycosides and amphotericin B were given as clinically indicated. Neutrophil engraftment was defined as the first of 3 consecutive days after transplantation that the ANC exceeded 0.5 Â 10 9 per l.
Glucose management protocol
In the IGC group, the blood glucose level was routinely tested every morning to adjust the dose of insulin so as to keep the level within the range of 80-110 mg per 100 ml.
Owing to the presence of fewer nursing staff in the HSCT unit than in the ICU, we replaced the continuous infusion of insulin with the addition of Humulin R to the bottle of PN to control the glucose level within the target range. In TPN, we universally added at least 1 unit of Humulin R per 10 g glucose. In patients who had an elevated blood glucose level, we also added Humulin R to the bottle of PN. We monitored the glucose level at least once a day in the morning as long as the level remained within the target range of 80-110 mg per 100 ml. When the glucose level became elevated, we increased the frequency of monitoring up to 2-4 times daily. In most patients, we adjusted the dose of insulin added to the bottle of PN as described in Table 2 . When the blood glucose level was 4180 mg per 100 ml or the dose of insulin was high, we manually adjusted the dose of Humulin R and administered insulin subcutaneously according to the attending physician's discretion. S.c. insulin administration usually consisted of 3-5 units at the beginning, and, if this was insufficient, the dose was manually adjusted by 2-4 units. When the patients received high-dose systemic steroid such as methylprednisolone 1-2 mg/kg per day for GVHD, we used the preprandial s.c. injection of insulin Aspart (NovoRapid) three times daily to avoid postprandial hyperglycemia and adjusted the dose according to the amount of food intake and the postprandial glucose level. When patients exhibited nausea, anorexia or vomiting, the amount of food intake became unstable. In such situations, insulin Aspart was injected immediately after the meal. When food intake was o50%, the dose was reduced or discontinued. Routine glucose monitoring was continued until PN was stopped, whereas the blood glucose level was maintained within the target range. Daily caloric intake was calculated by the dietitians. We tried to maintain oral intake as much as possible by using a suitable diet in jelly or liquid form. A dietitian adjusted the dose of supplemental PN to maintain the total caloric intake over 1.0 Â basal energy expenditure (BEE), and if the glucose level was stable, the nutritional intake could be increased up to 1.5 Â BEE. The glucose concentration in PN was usually started at 7.5% glucose as supplemental PN. The concentration was gradually increased to 12%, and, if necessary, this was further increased up to 18% to meet the target caloric intake. A lipid emulsion was also used to supply 10-30% of total caloric intake. The minimal total nutritional intake was set at 1.0 Â BEE because a retrospective analysis at our institute showed that caloric intake of more than 1.0 Â BEE was not associated with clinically significant wt loss. 17 To improve the glucose control, this level was set to be slightly lower Table 2 Protocol for adjustment of Humulin R ). There are two beneficial aspects of this protocol: we could maintain the minimal caloric intake with supplemental PN and we could immediately start insulin as required after the introduction of PN. The SGC group was managed without a specific protocol for nutrition practice and glucose control, although we routinely monitored blood glucose at least three times weekly to avoid severe hyperglycemia (blood glucose 4200 mg per 100 ml).
Outcome measures
Serially monitored glucose values were compared between the IGC group and the SGC group. We also analyzed the association between the mean glucose level during monitoring and the infection rate in both the SGC group and IGC group. Mean glucose levels were estimated for each patient and were categorized as follows: 80-110, 111-140, 141-179 and 4180. Glycemic variability, defined as the s.d. of the mean glucose value, was also analyzed. The outcome measures were time to the occurrence of documented infectious complications within 100 days after HSCT, time to each organ dysfunction defined as described below, time to grades II-IV and grades III-IV acute GVHD and time to NRM. These were calculated from the date of the start of the conditioning regimen. Organ dysfunction was defined with reference to van den Berghe 5-7 as follows: (1) hypercreatininemia; serum creatinine level X2.0 mg per 100 ml or more than twice the baseline, (2) hyperbilirubinemia; serum total bilirubin level X2.0 mg per 100 ml and (3) increased inflammatory markers; serum C-reactive protein (CRP) level X15 mg per 100 ml. In our institute, the CRP level was routinely monitored at least three times a week, as we previously reported that the preengraftment CRP level may predict a subsequent occurrence of acute GVHD and NRM after allogeneic HSCT. 19 These results suggested that CRP might be useful not only as a marker of infectious diseases but also as a surrogate marker for produced cytokines. Therefore, the serial changes of CRP level were compared between the two groups. Acute GVHD was graded by the consensus criteria. 20 
Statistical analyses
Baseline characteristics were summarized using descriptive statistics. The Student's t, w 2 and Wilcoxon rank-sum tests were used to compare clinical and patient characteristics. The probability of documented infectious complications and organ dysfunction were calculated using Kaplan-Meier estimates. A stratified Cox regression model, which accounts for the matched-cohort design, was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). On the basis of 64 patients, the study has an approximately 80% power to detect a HR of 0.5 for documented infections. The glucose values, measured repeatedly, were compared between groups using a repeated-measure analysis with a linear mixed-effect model. A level of Po0.05 was defined as statistically significant. All P-values are two-sided. All analyses were performed using SAS version 9.1.3 (Cary, NC, USA). Table 1 lists the patients' clinical and transplantation characteristics. Patients and transplantation characteristics were well balanced with the application of matching criteria. Nevertheless, in the IGC group, more patients received tacrolimus for GVHD prophylaxis (68 vs 36%, P ¼ 0.01) and more had a previous transplantation (32 vs 7%, P ¼ 0.01). The median duration of follow-up in surviving patients was 299 days (range, 78-607 days) in the IGC group and 1146 days (range, 329-1774 days) in the SGC group. 
Results
Patient characteristics
Hypoglycemia
In the IGC group, the incidence of mild hypoglycemia (CTCAE grades 1-2, glucose level 40-69 mg per 100 ml) was significantly higher than that in the SGC group (11 vs 3 patients, Po0.001). Although one patient (4.5%) in the IGC group who was diagnosed as type 2 diabetes mellitus developed severe hypoglycemia (CTCAE grade 3, glucose level 30-39 mg per 100 ml) with faintness, no patient developed seizure or loss of consciousness.
Glycemic variability
The mean glycemic variability in the SGC group and IGC group was 37.2 mg per 100 ml (range, 10.1-121.7 mg per 100 ml) and 27.5 mg per 100 ml (range, 11.3-46.6 mg per 100 ml), respectively, and glycemic variability in the IGC group tended to be lower than that in the SGC group (P ¼ 0.07).
TPN and insulin dosing
The percentage of patients who received TPN was 60% (25 patients) and 77% (17 patients) in the SGC group and the IGC group, respectively. The mean duration of TPN was 9 days (range, 0-35) and 13 days (range, 0-38) in the SGC group and IGC group, respectively. There was a tendency for more patients in the IGC group to receive TPN compared to the SGC group, but this difference was not statistically significant. The mean maximal dose of insulin (median (range), 51 (0-100) vs 2 (0-110) IU, Po0.001) and the mean maximal dose of insulin per 1 g parenteral glucose Infections Table 3 summarizes the results. In the IGC group, dramatically fewer patients developed documented infections within 100 days compared to the SGC group, as shown in Figure 3 .
Relation to mean glucose level
We also analyzed the association between the mean glucose level during monitoring and the infection rate in both the SGC and IGC groups. The incidence of infection was 34, 17, 67 and 40%, respectively, with mean glucose levels of 80-110, 111-140, 141-179 and X180. When we compared a lower glucose-level group (mean glucose level of 80-140) with a higher glucose-level group (mean glucose level of 4140), the incidence of infection was significantly higher in the latter group (28 vs 57%, P ¼ 0.042). When we assessed only patients with a lower glucose level, the IGC group tended to show a lower incidence of infectious diseases than the SGC group (14 vs 41%, P ¼ 0.061).
Relation to glycemic variability
We also analyzed the association between glycemic variability and the infection rate. The mean glycemic variability in patients with and without infection was 34.6 mg per 100 ml (range, 10.5-121.7 mg per 100 ml) and 33.3 mg per 100 ml (range, 10.1-110.6 mg per 100 ml), respectively, with no significant difference. As the importance of glycemic variability could vary among patients Intensive glucose control after HSCT S Fuji et al with different mean glucose levels, 21 we divided the patients into two groups based on mean glucose level 80-140 or 140 þ and then determined whether glycemic variability was associated with an increased incidence of infections. However, there was no significant association between glycemic variability and the incidence of infections in both groups. Figure 4 shows serial changes in the CRP level. Even though there was no difference in the CRP level between the two groups at the beginning of the conditioning regimen, the CRP level was significantly elevated in the SGC group compared to that in the IGC group 15 days after the beginning of the conditioning regimen, and this trend continued up to 40 days (Po0.05). The maximal CRP level during the neutropenic period in the IGC group was significantly lower than that in the SGC group (median (range), 6.9 (0.9-16.3) vs 11.5 (1.6-37.3), P ¼ 0.007).
CRP levels
Other clinical outcomes
The probability of grades II-IV acute GVHD within 100 days was 28 and 37% in the IGC and SGC groups (HR 1.05, 95% CI 0.38-2.91, P ¼ 0.93). The incidences of grades III-IV acute GVHD and NRM within 100 days were low in both groups (one and two patients, and one and one patient, in the IGC and SGC groups, respectively).
Discussion
This is the first study to evaluate the outcomes in allogeneic HSCT patients who were treated with a glucose management protocol. A salient finding of this study is that the incidence of documented infections, especially the incidence of bacteremia, was significantly lower in the IGC group than in the SGC group, as in a previous report in the ICU setting. 1 Moreover, there tended to be fewer organ dysfunctions in the IGC group, albeit this difference was not statistically significant. Furthermore, the CRP level, which might be a surrogate marker for produced cytokines, 19 was significantly lower in the IGC group than in the SGC group, as shown in Figure 4 . Even though this study did not have enough power to detect a decrease in acute GVHD and NRM, it could be anticipated that IGC could reduce the CRP level, which would lead to a reduced incidence of acute GVHD and NRM.
This study has several limitations. One limitation is that only 64 patients were analyzed with no sufficient power to demonstrate any statistically significant changes in the incidences of organ dysfunctions, which was similar to the result in a previous report in the ICU.
1,2 An additional limitation was that the control of the glucose level could be suboptimal. This could be because of the glucose control protocol, which included monitoring of glucose level and the administration of insulin. With regard to the administration of insulin, we replaced the continuous infusion of insulin with the addition of Humulin R to the bottle of PN to control the glucose level within the target range because of the presence of fewer nursing staff in the HSCT unit than in the ICU. This could delay the normalization of hyperglycemia. Even though severe hyperglycemia (4180 mg per 100 ml) was reduced, a glucose value within the normal range (80-110 mg per 100 ml) could be achieved in only 49% of the IGC group as shown in Figure 1b . From a methodological point of view, it might be inappropriate to simply count the number of glucose value measurements, as patients with hyperglycemia were monitored more frequently, as defined in this protocol. Furthermore, as the mode of glucose monitoring was quite different between the IGC group and the SGC group, it could be inappropriate to compare the glucose values. A future protocol should include a more appropriate monitoring of glucose level and administration of insulin system that assures the fine tuning of glucose levels within the target range. Finally, there was a possible selection bias that may have affected the results, as this study was not a randomized-control study and there were many nonparticipants. However, the incidence of documented infections in nonparticipants within 100 days after allogeneic HSCT was 42%. Therefore, the reduction in the incidence of documented infections in the IGC group could not simply be explained by other causes such as the selection of antibiotics or catheter management.
With these limitations in mind, we took several steps to improve the quality of the study. First, we carefully matched patients and transplantation characteristics. Second, the IGC strategy was applied prospectively. Third, the low rate of patients who developed clinically significant hypoglycemia should be emphasized. As previously reported, the IGC procedure becomes very difficult in the medical ICU, especially in patients who have sepsis, a high APACHE score or mechanical ventilation. 1, 2, 22, 23 The low rate of hypoglycemia could be because the medical acuity of our patients were relatively mild compared to those of patients in the medical ICU. Moreover, patients undergoing HSCT are younger and might have better b-cell function. The low rate of hypoglycemia could be important for maximizing the benefit of IGC because severe hypoglycemia could be associated with an increased risk of mortality. Values are mean þ s.e.
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The biological plausibility of the intervention should be discussed. The reduction in infectious diseases by IGC may reflect the deleterious effects of hyperglycemia on macrophage or neutrophil function or insulin-induced protective effects on mucosal and skin barriers. [24] [25] [26] [27] The improvement of innate immunity could be quite important, especially during the period of granulocytopenia after allogeneic HSCT. The protection of mucosal tissues could reduce bacterial translocation, which might lead to a reduced incidence of sepsis.
In conclusion, our results suggest that prospective IGC reduced the incidences of infectious diseases and organ dysfunction after allogeneic HSCT. To confirm these findings, a larger, prospective randomized-controlled trial is warranted.
